Investors are on the edge of their collective seats, hoping that Amphenol
What analysts say:
- Buy, sell, or hold?: The majority of analysts back Amphenol as a buy. But with 66.7% of analysts rating it a buy, Amphenol is still below the mean analyst rating of its nearest 10 competitors, which average 70.3% buys. Analysts like Amphenol better than competitor Molex overall. Six out of 11 analysts rate Molex a buy compared with six of nine for Amphenol. While analysts still rate the stock a moderate buy, they are a little more optimistic about it compared with three months ago.
- Revenue Forecasts: On average, analysts predict $1.01 billion in revenue this quarter. That would represent a rise of 6.5% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.78 per share. Estimates range from $0.76 to $0.80.
What our community says:
CAPS All Stars are solidly behind the stock with 98.8% granting it an "outperform" rating. The community at large agrees with the All Stars with 95.7% awarding it a rating of "outperform." Fools are gung-ho about Amphenol, though the message boards have been quiet lately with only 63 posts in the past 30 days. Even with a robust four out of five stars, Amphenol's CAPS rating falls a little short of the community's upbeat outlook.
Amphenol's profit has risen year over year by an average of 40.8% over the past five quarters.
One final thing: If you want to keep tabs on Amphenol movements, and for more analysis on the company, make sure you add it to your watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.